X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs CADILA HEALTHCARE - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH CADILA HEALTHCARE STERLING BIOTECH/
CADILA HEALTHCARE
 
P/E (TTM) x -0.4 18.5 - View Chart
P/BV x 0.0 4.2 0.3% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 STERLING BIOTECH   CADILA HEALTHCARE
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
CADILA HEALTHCARE
Mar-18
STERLING BIOTECH/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs11558 1.9%   
Low Rs3362 0.9%   
Sales per share (Unadj.) Rs26.8116.3 23.1%  
Earnings per share (Unadj.) Rs-15.017.9 -83.7%  
Cash flow per share (Unadj.) Rs-5.523.1 -23.6%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs54.985.4 64.3%  
Shares outstanding (eoy) m267.871,023.74 26.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.0 6.6%   
Avg P/E ratio x-0.525.7 -1.8%  
P/CF ratio (eoy) x-1.319.9 -6.4%  
Price / Book Value ratio x0.15.4 2.4%  
Dividend payout %019.6 0.0%   
Avg Mkt Cap Rs m1,862470,664 0.4%   
No. of employees `0001.411.8 11.5%   
Total wages/salary Rs m54718,545 2.9%   
Avg. sales/employee Rs Th5,303.310,072.7 52.7%   
Avg. wages/employee Rs Th403.81,569.1 25.7%   
Avg. net profit/employee Rs Th-2,959.01,547.7 -191.2%   
INCOME DATA
Net Sales Rs m7,181119,049 6.0%  
Other income Rs m431,132 3.8%   
Total revenues Rs m7,223120,181 6.0%   
Gross profit Rs m94728,475 3.3%  
Depreciation Rs m2,5435,388 47.2%   
Interest Rs m4,377911 480.5%   
Profit before tax Rs m-5,93123,308 -25.4%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9245,644 -34.1%   
Profit after tax Rs m-4,00718,292 -21.9%  
Gross profit margin %13.223.9 55.1%  
Effective tax rate %32.424.2 134.0%   
Net profit margin %-55.815.4 -363.1%  
BALANCE SHEET DATA
Current assets Rs m14,33582,005 17.5%   
Current liabilities Rs m49,80960,720 82.0%   
Net working cap to sales %-494.017.9 -2,763.1%  
Current ratio x0.31.4 21.3%  
Inventory Days Days40373 551.5%  
Debtors Days Days17198 173.6%  
Net fixed assets Rs m55,43283,703 66.2%   
Share capital Rs m2681,024 26.2%   
"Free" reserves Rs m13,93586,421 16.1%   
Net worth Rs m14,70187,445 16.8%   
Long term debt Rs m9,47825,551 37.1%   
Total assets Rs m73,988180,653 41.0%  
Interest coverage x-0.426.6 -1.3%   
Debt to equity ratio x0.60.3 220.6%  
Sales to assets ratio x0.10.7 14.7%   
Return on assets %0.510.6 4.7%  
Return on equity %-27.320.9 -130.3%  
Return on capital %-6.422.0 -29.2%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86042,683 4.4%   
Fx outflow Rs m2511,242 0.2%   
Net fx Rs m1,83531,441 5.8%   
CASH FLOW
From Operations Rs m1,7199,193 18.7%  
From Investments Rs m-3,148-9,737 32.3%  
From Financial Activity Rs m1,426515 276.9%  
Net Cashflow Rs m-3-29 11.7%  

Share Holding

Indian Promoters % 33.9 74.8 45.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.3 -  
FIIs % 9.9 5.9 167.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 11.0 357.3%  
Shareholders   21,482 44,069 48.7%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare STERLING BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 260 Points Down; TCS & Infosys Top Losers(12:30 pm)

Stock markets in India are presently trading lower, tracking weakness in their global peers. Among the sectoral indices, IT stocks and metal stocks are witnessing maximum selling pressure.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS